Fig. 6

Relationships of Risk Score with tumor immune characteristics and clinical application. Differences in the distributions of immune cells (a), immune scores (b), expression of immune checkpoint genes (c), TIDE score (d), and therapeutic response state (e) between low- and high-risk groups. f Kaplan–Meier survival analysis of patients in the low- and high-risk groups in the IMvigor210 dataset. g Estimation of drug sensitivity between the low- and high-risk groups